Form 13-F position report

HAVARD BIOSCIENCE INC

Reported by Granahan Investment Management LLC

HBIO CUSIP 416906105 Manager CIK 0001026710

Reported 1,532,693 shares, up 75,944 (5.2%) from the prior quarter.

Reported value -39.0%; share count 5.2% vs. the prior quarter.

Added
% of reported 13F value 0.19% This manager · Q2 2022
Shares 1,532,693 Quarter-end amount reported
Reported value $5,518,000 Fair value at quarter end
Consecutive quarters held 37 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 11026000
2021-12-31 11688000
2022-03-31 9046000
2022-06-30 5518000
2022-09-30 3823000
2022-12-31 4051006
2023-03-31 6006634
2023-06-30 7902581
2023-09-30 7462960
2023-12-31 9862639
2024-03-31 7902300
2024-06-30 5487384
2024-09-30 5018004
2024-12-31 3412246
2025-03-31 864788
2025-06-30 666369
2025-09-30 264643
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for HAVARD BIOSCIENCE INC held by Granahan Investment Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -603,519 (-100.0%) 0 $0 2026-02-17
Q3 2025 Reduced 603,519 -897,989 (-59.8%) 0.01% $264,643 2025-11-14
Q2 2025 Reduced 1,501,508 -26,386 (-1.7%) 0.03% $666,369 2025-08-14
Q1 2025 Reduced 1,527,894 -89,284 (-5.5%) 0.04% $864,788 2025-05-15
Q4 2024 Reduced 1,617,178 -248,251 (-13.3%) 0.14% $3,412,246 2025-02-14
Q3 2024 Reduced 1,865,429 -59,969 (-3.1%) 0.2% $5,018,004 2024-11-14
Q2 2024 Added 1,925,398 +61,648 (3.3%) 0.22% $5,487,384 2024-08-14
Q1 2024 Added 1,863,750 +20,266 (1.1%) 0.28% $7,902,300 2024-05-15
Q4 2023 Added 1,843,484 +107,912 (6.2%) 0.33% $9,862,639 2024-02-14
Q3 2023 Added 1,735,572 +296,122 (20.6%) 0.27% $7,462,960 2023-11-14
Q2 2023 Added 1,439,450 +9,299 (0.7%) 0.24% $7,902,581 2023-08-14
Q1 2023 Reduced 1,430,151 -32,306 (-2.2%) 0.18% $6,006,634 2023-05-15
Q4 2022 Reduced 1,462,457 -30,812 (-2.1%) 0.12% $4,051,006 2023-02-14
Q3 2022 Reduced 1,493,269 -39,424 (-2.6%) 0.12% $3,823,000 2022-11-14
Q2 2022 Added 1,532,693 +75,944 (5.2%) 0.19% $5,518,000 2022-08-15
Q1 2022 Reduced 1,456,749 -201,074 (-12.1%) 0.22% $9,046,000 2022-05-16
Q4 2021 Added 1,657,823 +78,168 (4.9%) 0.24% $11,688,000 2022-02-14
Q3 2021 Added 1,579,655 +40,095 (2.6%) 0.21% $11,026,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

115 managers reported HAVARD BIOSCIENCE INC for Q2 2022.

Managers reporting HAVARD BIOSCIENCE INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Harvey Partners LLC Added 2,865,000 +639,000 2.27% $10,314,000 12 qtrs
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT INC Added 2,654,247 +188,837 0.67% $9,555,000 9 qtrs
Portolan Capital Management LLC Reduced 2,451,861 -74,928 0.89% $8,827,000 9 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 1,877,842 -208 < 0.01% $6,760,000 37 qtrs
ROYCE & ASSOCIATES LP Reduced 1,620,263 -65,700 0.06% $5,833,000 37 qtrs
B Riley Asset Management LLC Added 1,544,647 +646,211 2.66% $5,561,000 3 qtrs
VANGUARD GROUP INC Reduced 1,538,283 -386,234 < 0.01% $5,538,000 37 qtrs
Granahan Investment Management LLC This report Added 1,532,693 +75,944 0.19% $5,518,000 37 qtrs
AMH Equity Ltd Added 1,250,000 +473,747 7.77% $4,500,000 3 qtrs
BlackRock Inc Reduced 1,209,119 -1,848,883 < 0.01% $4,353,000 22 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,455,411
Shared
0
None
77,282

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.